AGAdolfo Garcia-Ocaña

Adolfo Garcia-Ocaña

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adolfo Garcia-Ocaña has a total of 191 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew F. Stewart

    Diabetes, Obesity and Metabolism Institute, and Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, USA

    7 shared publications
  • Carolina Rosselot

    Diabetes Obesity and Metabolism Institute, and Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai

    7 shared publications
  • Geming Lu

    Department of Molecular and Cellular Endocrinology, Arthur Riggs Diabetes and Metabolism Research Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA, USA

    7 shared publications
  • Andrew F. Stewart

    Diabetes, Obesity and Metabolism Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, USA

    6 shared publications
  • Donald K. Scott

    Diabetes, Obesity and Metabolism Institute, and Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai, New York, USA

    6 shared publications
  • Donald K. Scott

    Diabetes Obesity and Metabolism Institute, and Division of Endocrinology, Diabetes and Bone Diseases, Icahn School of Medicine at Mount Sinai

    5 shared publications

Latest Publications

  • Open Access

    Bistable regulation of adipocyte heterogeneity governs thermogenesis

    by Anying Song, Yifan Wang, Guan Wang, Marie Bae, Zhichao Wang, Guoming Gao, Zhuyin Wu, Geming Lu, Jieyi Meng, Jiayu Yu, et al.

    Brown adipocytes (BAs) are thermogenic cells that regulate energy homeostasis, and age-related declines in thermogenesis contribute to cold sensitivity 1–5 . We previously identified a BA subpopulation with low UCP1 expression (hereafter, BA-L cells) that coexists with the classical, high-UCP1-expressing BAs (hereafter, BA-H cells) 6 . Here we show that IL-1β secreted by neutrophils and macrophages stabilizes nearby BAs in the BA-L state. Specifically, IL-1β stabilizes hexose-6-phosphate dehydrogenase (H6PD) protein from degradation to ensure the generation of active glucocorticoids, which activate the glucocorticoid receptor (GR, encoded by Nr3c1 ) and increase the expression of its target gene, regulator of G-protein signalling 2 ( Rgs2 ), thereby suppressing UCP1 expression. Cold exposure reduces IL-1β levels, depending on sympathetic innervation, leading to H6PD degradation and the conversion of BA-L cells to BA-H cells, thereby enhancing UCP1-dependent thermogenesis. Rising environmental temperatures trigger the opposite events. BA-specific inducible deletion of Nr3c1 during cold exposure locks these cells in the BA-H state, leading to persistent thermogenesis and increased energy expenditure days after the mice return to room temperature. Notably, IL-1β is elevated in aged brown adipose tissue, resulting in a locked low BA-H/BA-L ratio and cold intolerance. Suppressing GR in aged mice restores the BA-H/BA-L ratio, resumes thermogenesis and increases energy expenditure. Our findings reveal a spatiotemporal neuronal–immune regulation of BA heterogeneity that governs thermogenesis and offers a fundamental understanding of the mechanisms underlying increased cold sensitivity in older individuals.

  • Open Access

    Harmine Plus Exendin-4 Enhances Remission of Recent-Onset Type 1 Diabetes Following Anti-CD3 Therapy

    by Geming Lu, Randy Kang, Miguel Varela, Eunjin Oh, Yansui Li, Jungeun Lee, Leah Kebrom, Juan Aldaco, Jiamin Zhang, Madeline Wichman, et al.

    Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic β-cells. While anti-CD3 therapy can delay disease progression and preserve residual β-cell function, disease reversal will likely require both immune modulation and β-cell regeneration. We found that the combination of harmine and exendin-4 (H+E) reduced inflammation-induced human β-cell apoptosis, suppressed cytokine signaling and immunogenicity pathways, and improved β-cell function. Although H+E alone did not reverse diabetes in NOD mice, low-dose anti-CD3 followed by H+E normalized blood glucose, increased insulin levels, improved glucose tolerance, expanded β-cell mass, and enhanced diabetes remission. These effects were associated with reduced pro-inflammatory T-cell responses, increased regulatory T cells, and greater expression of exhaustion-related T-cell markers, without broad lymphocyte depletion. Similar immunomodulatory effects were observed in activated human PBMCs. Transcriptomic analyses identified the lncRNA SNHG6 as a key mediator of H+E action; SNHG6 protected β-cells from cytokine-induced stress, apoptosis, and immunogenicity. Together, these findings demonstrate that H+E promotes β-cell recovery and resilience while reducing β-cell immunogenicity, enabling remission of recent-onset T1D when combined with anti-CD3 therapy. SNHG6 emerges as a novel regulator of β-cell protection during inflammation.

  • Open Access

    Human pancreatic α-cell heterogeneity and trajectory inference analyses reveal SMOC1 as a β-cell dedifferentiation gene

    by Randy B. Kang, Miguel Varela, Eunjin Oh, Jungeun Lee, Tuo Zhang, Esra Karakose, Andrew F. Stewart, Donald K. Scott, Debbie C. Thurmond, Adolfo Garcia-Ocana, et al.

    β-cell dysfunction and dedifferentiation towards an α-cell-like phenotype are hallmarks of type 2 diabetes. However, the cell subtypes involved in β-to-α-cell transition are unknown. Using single-cell and single-nucleus RNA-seq, RNA velocity, PAGA/cell trajectory inference, and gene commonality, we interrogated α-β-cell fate switching in human islets. We found five α-cell subclusters with distinct transcriptomes. PAGA analysis showed bifurcating cell trajectories in non-diabetic while unidirectional cell trajectories from β-to-α-cells in type 2 diabetes islets suggesting dedifferentiation towards α-cells. Ten genes comprised the common signature genes in trajectories towards α-cells. Among these, the α-cell gene SMOC1 was expressed in β-cells in type 2 diabetes. Enhanced SMOC1 expression in β-cells decreased insulin expression and secretion and increased β-cell dedifferentiation markers. Collectively, these studies reveal differences in α-β-cell trajectories in non-diabetes and type 2 diabetes human islets, identify signature genes for β-to-α-cell trajectories, and discover SMOC1 as an inducer of β-cell dysfunction and dedifferentiation.


  • Top Cited Papers
    Open Access

    Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease

    by R. M. Imtiaz Karim Rony, Alireza Shokrani, Naseeb Kaur Malhi, Deborah Hussey, Rachael Mooney, Zhen Bouman Chen, Tristan Scott, Haiyong Han, Jaeger Moore, Jiahui Liu, et al.

    Therapeutic plasma exchange (TPE) is a blood purification technique which functions to remove pathological plasma constituents such as autoantibodies, inflammatory cytokines, immune complexes, and extracellular vesicles (EVs) that contribute to a range of disease states. In this review, we examine current and emerging indications for TPE across cardiovascular, metabolic, neurological, inflammatory, and oncological diseases. We cover emerging preclinical animal models and new applications, emphasizing the roles of cellular signaling and EV biology in mediating plasma functions, and discuss unique therapeutic “windows of opportunity” offered by TPE. We conclude that TPE is underutilized in both preventative and precision medicine, and that next generation TPE therapies will involve personalized plasma biomarker and modulation feedback, with synergistic plasma infusion therapies to mitigate age associated disease and promote tissue rejuvenation.


  • Harmine and exendin-4 combination therapy safely expands human β cell mass in vivo in a mouse xenograft system

    by Carolina Rosselot, Yansui Li, Peng Wang, Alexandra Alvarsson, Kara Beliard, Geming Lu, Randy Kang, Rosemary Li, Hongtao Liu, Virginia Gillespie, et al.

    Five hundred thirty-seven million people globally suffer from diabetes. Insulin-producing β cells are reduced in number in most people with diabetes, but most individuals still have some residual β cells. However, none of the many diabetes drugs in common use increases human β cell numbers. Recently, small molecules that inhibit dual tyrosine-regulated kinase 1A (DYRK1A) have been shown to induce immunohistochemical markers of human β cell replication, and this is enhanced by drugs that stimulate the glucagon-like peptide 1 (GLP1) receptor (GLP1R) on β cells. However, it remains to be demonstrated whether these immunohistochemical findings translate into an actual increase in human β cell numbers in vivo. It is also unknown whether DYRK1A inhibitors together with GLP1R agonists (GLP1RAs) affect human β cell survival. Here, using an optimized immunolabeling-enabled three-dimensional imaging of solvent-cleared organs (iDISCO + ) protocol in mouse kidneys bearing human islet grafts, we demonstrate that combination of a DYRK1A inhibitor with exendin-4 increases actual human β cell mass in vivo by a mean of four- to sevenfold in diabetic and nondiabetic mice over 3 months and reverses diabetes, without alteration in human α cell mass. The augmentation in human β cell mass occurred through mechanisms that included enhanced human β cell proliferation, function, and survival. The increase in human β cell survival was mediated, in part, by the islet prohormone VGF. Together, these findings demonstrate the therapeutic potential and favorable preclinical safety profile of the DYRK1A inhibitor–GLP1RA combination for diabetes treatment.


  • Open Access

    Human Pancreatic α-Cell Heterogeneity and Trajectory Inference Analysis Using Integrated Single Cell- and Single Nucleus-RNA Sequencing Platforms

    by Randy B. Kang, Jungeun Lee, Miguel Varela, Yansui Li, Carolina Rosselot, Tuo Zhang, Esra Karakose, Andrew F. Stewart, Donald K. Scott, Adolfo Garcia-Ocana, et al.

    Prior studies have shown that pancreatic α-cells can transdifferentiate into β-cells, and that β-cells de-differentiate and are prone to acquire an α-cell phenotype in type 2 diabetes (T2D). However, the specific human α-cell and β-cell subtypes that are involved in α-to-β-cell and β-to-α-cell transitions are unknown. Here, we have integrated single cell RNA sequencing (scRNA-seq) and single nucleus RNA-seq (snRNA-seq) of isolated human islets and human islet grafts and provide additional insight into α-β cell fate switching. Using this approach, we make seven novel observations. 1) There are five different GCG -expressing human α-cell subclusters [α1, α2, α-β-transition 1 (AB-Tr1), α-β-transition 2 (AB-Tr2), and α-β (AB) cluster] with different transcriptome profiles in human islets from non-diabetic donors. 2) The AB subcluster displays multihormonal gene expression, inferred mostly from snRNA-seq data suggesting identification by pre-mRNA expression. 3) The α1, α2, AB-Tr1, and AB-Tr2 subclusters are enriched in genes specific for α-cell function while AB cells are enriched in genes related to pancreatic progenitor and β-cell pathways; 4) Trajectory inference analysis of extracted α- and β-cell clusters and RNA velocity/PAGA analysis suggests a bifurcate transition potential for AB towards both α- and β-cells. 5) Gene commonality analysis identifies ZNF385D, TRPM3, CASR, MEG3 and HDAC9 as signature for trajectories moving towards β-cells and SMOC1, PLCE1, PAPPA2, ZNF331, ALDH1A1, SLC30A8, BTG2, TM4SF4, NR4A1 and PSCK2 as signature for trajectories moving towards α-cells. 6) Remarkably, in contrast to the events in vitro , the AB subcluster is not identified in vivo in human islet grafts and trajectory inference analysis suggests only unidirectional transition from α-to-β-cells in vivo . 7) Analysis of scRNA-seq datasets from adult human T2D donor islets reveals a clear unidirectional transition from β-to-α-cells compatible with dedifferentiation or conversion into α-cells. Collectively, these studies show that snRNA-seq and scRNA-seq can be leveraged to identify transitions in the transcriptional status among human islet endocrine cell subpopulations in vitro , in vivo , in non-diabetes and in T2D. They reveal the potential gene signatures for common trajectories involved in interconversion between α- and β-cells and highlight the utility and power of studying single nuclear transcriptomes of human islets in vivo . Most importantly, they illustrate the importance of studying human islets in their natural in vivo setting.


  • Open Access

    Single-nucleus RNA sequencing of human pancreatic islets identifies novel gene sets and distinguishes β-cell subpopulations with dynamic transcriptome profiles

    by Randy B. Kang, Yansui Li, Carolina Rosselot, Tuo Zhang, Mustafa Siddiq, Prashant Rajbhandari, Andrew F. Stewart, Donald K. Scott, Adolfo Garcia-Ocana, Geming Lu

    Background: Single-cell RNA sequencing (scRNA-seq) provides valuable insights into human islet cell types and their corresponding stable gene expression profiles. However, this approach requires cell dissociation that complicates its utility in vivo. On the other hand, single-nucleus RNA sequencing (snRNA-seq) has compatibility with frozen samples, elimination of dissociation-induced transcriptional stress responses, and affords enhanced information from intronic sequences that can be leveraged to identify pre-mRNA transcripts. Methods: We obtained nuclear preparations from fresh human islet cells and generated snRNA-seq datasets. We compared these datasets to scRNA-seq output obtained from human islet cells from the same donor. We employed snRNA-seq to obtain the transcriptomic profile of human islets engrafted in immunodeficient mice. In both analyses, we included the intronic reads in the snRNA-seq data with the GRCh38-2020-A library. Results: First, snRNA-seq analysis shows that the top four differentially and selectively expressed genes in human islet endocrine cells in vitro and in vivo are not the canonical genes but a new set of non-canonical gene markers including ZNF385D, TRPM3, LRFN2, PLUT (β-cells); PTPRT, FAP, PDK4, LOXL4 (α-cells); LRFN5, ADARB2, ERBB4, KCNT2 (δ-cells); and CACNA2D3, THSD7A, CNTNAP5, RBFOX3 (γ-cells). Second, by integrating information from scRNA-seq and snRNA-seq of human islet cells, we distinguish three β-cell sub-clusters: an INS pre-mRNA cluster (β3), an intermediate INS mRNA cluster (β2), and an INS mRNA-rich cluster (β1). These display distinct gene expression patterns representing different biological dynamic states both in vitro and in vivo. Interestingly, the INS mRNA-rich cluster (β1) becomes the predominant sub-cluster in vivo. Conclusions: In summary, snRNA-seq and pre-mRNA analysis of human islet cells can accurately identify human islet cell populations, subpopulations, and their dynamic transcriptome profile in vivo.


  • Open Access

    Single Nucleus RNA Sequencing of Human Pancreatic Islets In Vitro and In Vivo Identifies New Gene Sets and Three β-Cell Subpopulations with Different Transcriptional Profile

    by Randy B. Kang, Yansui Li, Carolina Rosselot, Tuo Zhang, Mustafa Siddiq, Prashant Rajbhandari, Andrew F. Stewart, Donald K. Scott, Adolfo Garcia-Ocana, Geming Lu

    Single-cell RNA sequencing (scRNA-seq) has provided valuable insights into human islet cell types and their corresponding stable gene expression profiles. However, this approach requires cell dissociation that complicates its utility in vivo and provides limited information on the active transcriptional status of islet cells. On the other hand, single-nucleus RNA sequencing (snRNA-seq) does not require cell dissociation and affords enhanced information from intronic sequences that can be leveraged to identify actively transcribing genes in islet cell populations. Here, we first sought to compare scRNA-seq and snRNA-seq analysis of human islets in vitro using exon reads or combined exon and intron reads, respectively. Datasets reveal similar human islet cell clusters using both approaches. In the snRNA-seq data, however, the top differentially expressed genes in human islet endocrine cells are not the canonical genes but a new set of non-canonical gene markers including ZNF385D, TRPM3, LRFN2, PLUT (β cells), PTPRT, FAP, PDK4, LOXL4 (α cells), LRFN5, ADARB2, ERBB4, KCNT2 (δ cells) and CACNA2D3, THSD7A, CNTNAP5, RBFOX3 (γ cells). Notably, these markers also accurately define endocrine cell populations in human islet grafts in vivo . Further, by integrating the information from nuclear and cytoplasmic transcriptomes, we identify three β-cell sub-clusters: an active INS mRNA transcribing cluster (β1), an intermediate INS mRNA-transcribing cluster (β2), and a mature INS mRNA rich cluster (β3). These display distinct gene expression patterns representing different biological dynamic states both in vitro and in vivo . Interestingly, the INS mRNA rich cluster (β3) becomes the predominant sub-cluster in vivo . In summary, snRNA-seq analysis of human islet cells is a previously unrecognized tool that can be accurately employed for improved identification of human islet cell types and their transcriptional status in vivo .


  • Open Access

    GLP-1 receptor signaling increases PCSK1 and β cell features in human α cells

    by Mridusmita Saikia, Marlena M. Holter, Leanne R. Donahue, Isaac S. Lee, Qiaonan C. Zheng, Journey L. Wise, Jenna E. Todero, Daryl J. Phuong, Darline Garibay, Reilly Coch, et al.

    Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. GLP-1 is classically produced by gut L cells; however, under certain circumstances α cells can express the prohormone convertase required for proglucagon processing to GLP-1, prohormone convertase 1/3 (PC1/3), and can produce GLP-1. However, the mechanisms through which this occurs are poorly defined. Understanding the mechanisms by which α cell PC1/3 expression can be activated may reveal new targets for diabetes treatment. Here, we demonstrate that the GLP-1 receptor (GLP-1R) agonist, liraglutide, increased α cell GLP-1 expression in a β cell GLP-1R–dependent manner. We demonstrate that this effect of liraglutide was translationally relevant in human islets through application of a new scRNA-seq technology, DART-Seq. We found that the effect of liraglutide to increase α cell PC1/3 mRNA expression occurred in a subcluster of α cells and was associated with increased expression of other β cell–like genes, which we confirmed by IHC. Finally, we found that the effect of liraglutide to increase bihormonal insulin + glucagon + cells was mediated by the β cell GLP-1R in mice. Together, our data validate a high-sensitivity method for scRNA-seq in human islets and identify a potentially novel GLP-1–mediated pathway regulating human α cell function.


  • Open Access

    The many lives of Myc in the pancreatic β-cell

    by Carolina Rosselot, Sharon Baumel-Alterzon, Yansui Li, Gabriel Brill, Luca Lambertini, Liora S. Katz, Geming Lu, Adolfo Garcia-Ocaña, Donald K. Scott